SEC Comment Letter 0000000000-25-001047 to Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD.
Date: Jan. 31, 2025 · CIK: 0001962011 · Accession: 0000000000-25-001047
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284569
Letter
January 31, 2025 John Yu Chief Executive Officer Kairos Pharma, LTD. 2355 Westwood Blvd., #139 Los Angeles, CA 90064 Re:Kairos Pharma, LTD. Registration Statement on Form S-1 Filed January 29, 2025 File No. 333-284569 Dear John Yu: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Megan J. Penick
Show Raw Text
January 31, 2025
John Yu
Chief Executive Officer
Kairos Pharma, LTD.
2355 Westwood Blvd., #139
Los Angeles, CA 90064
Re:Kairos Pharma, LTD.
Registration Statement on Form S-1
Filed January 29, 2025
File No. 333-284569
Dear John Yu:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Megan J. Penick